A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 405 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR More Than 25 Additional Years Needed to Slow an Increasing Incidence... September 8, 2021 ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... December 29, 2021 Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... January 13, 2021 How to Find Reliable and Affordable Transportation During Cancer January 23, 2024 Load more HOT NEWS Courageous children receive Star Awards in virtual celebration Stem cell research: meet the scientist growing ‘mini guts’ in her... OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement...
